Press releases
-
ICON plc provides update on vaccine study
On August 12, 2025, ICON plc, announced that the large-scale next generation COVID vaccine study that was highlighted on our earnings call on July 24, 2025 as restarted and actively enrolling, has now had a stop work notice issued by BARDA to the sponsor.
-
ICON announces results of annual general meeting
ICON plc today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders.
-
ICON reports second quarter 2025 results
ICON plc today reported its financial results for the second quarter ended June 30, 2025.
-
ICON’s leadership and performance in phase 1 clinical trials recognised in independent industry benchmarking report
ICON plc has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR).
-
ICON and its employees recognised as clinical research industry leaders, and for innovation and progress in sustainability
ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards.
-
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
ICON plc today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025.
-
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
ICON plc today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025 at 10.40 am CT.
-
ICON releases its ICON Cares 2024 Report
The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program.
-
.jpeg?crop=yes&w=545&h=545&itok=tbzan7eM "obesity scan person")
Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
ICON report first quarter 2025 results
Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue.
.jpeg?crop=yes&w=340&h=340&itok=RvNJkYv7 "obesity scan person"){kind=icon}
